Find your next M&A target

Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.

Project details

Japanese biopharmaceutical start-up seeks investment

Project region Japan
Industry Biomedicine
Total value of the target N/A
Expected target net rate of return after deducting all taxes and fees N/A
Validity period of pending order 365

CONTACT ADVISOR

  • Simon Laube

    Simon Laube

    Senior Associate, International Business Advisory

Project highlights tumor antigen peptide vaccines - good safety and efficacy data
Project description

The Japanese biopharmaceutical start-up is developing tumor antigen peptide vaccines and authorizing immunologic adjuvants. The tumor antigen peptide vaccines are tumor polypeptide antigens (HSP70/GPC3 peptides) which can be combined with three different types of white blood cells (HLA-A2402, HLA-A0201, HLA-A0206). The other component - immunologic adjuvants - have been recognized in clinical trials with good safety and efficacy data; it has already been applied for patent and is planning to conduct Phase 1 and Phase 2 clinical trials.

Enquire for more information about our services, and how we can help solve challenges for your organization

Contact Us
The code is case-sensitive